New cancer drug combo enters first human tests

NCT ID NCT06205706

Ongoing Disease control Sponsor: BioInvent International AB Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This early-phase trial is testing an experimental drug called BI-1910, alone or with the immunotherapy pembrolizumab, in people with advanced solid tumors (including lung and liver cancers) that have worsened after standard treatments. The main goals are to see if the drug is safe, tolerable, and to find the best dose for future studies. Only 35 participants will be enrolled, and they will receive the drug by infusion every three weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BI-1910 (an experimental antibody) and pembrolizumab (an immunotherapy)
What this could lead to: If successful, this could point toward a new treatment option for advanced solid tumors that have stopped responding to standard therapies.
What could go wrong: This is a very early, first-in-human trial with only 35 participants. It is designed mainly to check safety and dosing, not to prove effectiveness. Many early-stage cancer drugs do not advance to later trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA NON-SMALL CELL LUNG CANCER SOLID TUMORS

Contacts and locations

Locations

HM Sanchinarro

Madrid, Spain
Hospital Fundacion Jimenez Diaz

Madrid, Spain
Hospital HM Nou Delfos

Barcelona, 08023, Spain
Hospital universitario Virgen del Rocio

Seville, Spain
Karolinska University Hospital, Solna

Stockholm, Sweden
Lund University Hospital

Lund, Sweden
Rigshospitalet

Copenhagen, Denmark
Universitätsklinikum Essen

Essen, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.